The Medical Letter on Drugs and Therapeutics
Cervarix - A Second HPV Vaccine
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved a recombinant human papillomavirus (HPV) vaccine (Cervarix – GlaxoSmithKline) for use in girls and women 10-25 years old to prevent infection with HPV types 16 and 18, which have been associated with cervical cancer. A recombinant quadrivalent HPV vaccine (Gardasil – Merck) already on the market in the US prevents infection with HPV types 6, 11, 16 and 18.1

BACKGROUND — HPV is commonly acquired by young women soon after initiation of sexual activity, with a cumulative incidence of 40% within 16 months.2 Although most HPV infections clear spontaneously without clinical sequelae, persistent infection can cause abnormalities in the cervical epithelium that may progress to cancer. HPV types 16 and 18 are responsible for more than 70% of cervical cancers and high-grade cervical intraepithelial neoplasia (CIN), a precursor of cervical cancer. ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Cervarix - A Second HPV Vaccine
Article code: 1338a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian